TG Therapeutics

$6.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.32 (-4.71%) Today
$0.00 (0.00%) As of 4:08 PM EDT after-hours

Why Robinhood?

You can buy or sell TGTX and other stocks, options, ETFs, and crypto commission-free!

About TGTX

TG Therapeutics, Inc. Common Stock, also called TG Therapeutics, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Read More Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Employees
105
Headquarters
New York, New York
Founded
1993
Market Cap
613.63M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.12M
High Today
$6.83
Low Today
$6.47
Open Price
$6.80
Volume
1.04M
52 Week High
$11.00
52 Week Low
$3.32

Collections

TGTX Earnings

-$0.68
-$0.59
-$0.50
-$0.41
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.